At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study of MUC1 Vaccine in Current and Former Smokers at High Risk for Lung Cancer
In Brief
A Phase 1 clinical trial evaluating Laboratory Biomarker Analysis and MUC1 Peptide-Poly-ICLC Vaccine for Lung Carcinoma. Active but no longer recruiting, targeting 50 participants across 2 sites.
Signals
Detailed Summary
This pilot phase I trial studies the side effects and how well MUC1 peptide-Poly-ICLC vaccine works in preventing lung cancer in current and former smokers at high risk for lung cancer. Vaccines made from peptides may help the body build an effective immune response to kill cells. MUC1 peptide-Poly-ICLC vaccine may stimulate the body's immune system and slow or stop the changes from normal to pre-cancer to cancer.
Study Details
Timeline
Arms & Interventions
Patients receive MUC1 peptide-Poly-ICLC vaccine SC at weeks 0, 2, and 10.
Interventions
Correlative studies
Given SC